Cargando…
Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients
Renal transplantation has become the sole most preferred therapy modality for end-stage renal disease patients. The growing tendency for renal transplants, and prolonged survival of renal recipients, have resulted in a certain number of post-transplant colorectal cancer patients. Antitumor pharmacot...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759705/ https://www.ncbi.nlm.nih.gov/pubmed/31579127 http://dx.doi.org/10.1177/1758835919876196 |
_version_ | 1783453745998200832 |
---|---|
author | Fu, Yuanyuan Liao, Chengheng Cui, Kai Liu, Xiao Fang, Wentong |
author_facet | Fu, Yuanyuan Liao, Chengheng Cui, Kai Liu, Xiao Fang, Wentong |
author_sort | Fu, Yuanyuan |
collection | PubMed |
description | Renal transplantation has become the sole most preferred therapy modality for end-stage renal disease patients. The growing tendency for renal transplants, and prolonged survival of renal recipients, have resulted in a certain number of post-transplant colorectal cancer patients. Antitumor pharmacotherapy in these patients is a dilemma. Substantial impediments such as carcinogenesis of immunosuppressive drugs (ISDs), drug interaction between ISDs and anticancer drugs, and toxicity of anticancer drugs exist. However, experience of antitumor pharmacotherapy in these patients is limited, and the potential risks and benefits have not been reviewed systematically. This review evaluates the potential impediments, summarizes current experience, and provides potential antitumor strategies, including adjuvant, palliative, and subsequent regimens. Moreover, special pharmaceutical care, such as ISDs therapeutic drug monitoring, metabolic enzymes genotype, and drug interaction, are also highlighted. |
format | Online Article Text |
id | pubmed-6759705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-67597052019-10-02 Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients Fu, Yuanyuan Liao, Chengheng Cui, Kai Liu, Xiao Fang, Wentong Ther Adv Med Oncol Review Renal transplantation has become the sole most preferred therapy modality for end-stage renal disease patients. The growing tendency for renal transplants, and prolonged survival of renal recipients, have resulted in a certain number of post-transplant colorectal cancer patients. Antitumor pharmacotherapy in these patients is a dilemma. Substantial impediments such as carcinogenesis of immunosuppressive drugs (ISDs), drug interaction between ISDs and anticancer drugs, and toxicity of anticancer drugs exist. However, experience of antitumor pharmacotherapy in these patients is limited, and the potential risks and benefits have not been reviewed systematically. This review evaluates the potential impediments, summarizes current experience, and provides potential antitumor strategies, including adjuvant, palliative, and subsequent regimens. Moreover, special pharmaceutical care, such as ISDs therapeutic drug monitoring, metabolic enzymes genotype, and drug interaction, are also highlighted. SAGE Publications 2019-09-23 /pmc/articles/PMC6759705/ /pubmed/31579127 http://dx.doi.org/10.1177/1758835919876196 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Fu, Yuanyuan Liao, Chengheng Cui, Kai Liu, Xiao Fang, Wentong Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients |
title | Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients |
title_full | Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients |
title_fullStr | Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients |
title_full_unstemmed | Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients |
title_short | Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients |
title_sort | antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759705/ https://www.ncbi.nlm.nih.gov/pubmed/31579127 http://dx.doi.org/10.1177/1758835919876196 |
work_keys_str_mv | AT fuyuanyuan antitumorpharmacotherapyofcolorectalcancerinkidneytransplantrecipients AT liaochengheng antitumorpharmacotherapyofcolorectalcancerinkidneytransplantrecipients AT cuikai antitumorpharmacotherapyofcolorectalcancerinkidneytransplantrecipients AT liuxiao antitumorpharmacotherapyofcolorectalcancerinkidneytransplantrecipients AT fangwentong antitumorpharmacotherapyofcolorectalcancerinkidneytransplantrecipients |